Literature DB >> 31403940

LncRNA ZFAS1 promotes proliferation and migration and inhibits apoptosis in nasopharyngeal carcinoma via the PI3K/AKT pathway in vitro.

Xiaoqiong Wang1, Qiaozhi Jin2, Xue Wang3, Wubing Chen2, Zhiyi Cai2.   

Abstract

BACKGROUND: Increasing evidence shows that long non-coding RNAs (lncRNAs) play a key role in the development of various cancers. Zinc finger antisense 1 (ZFAS1) is a novel lncRNA with previously demonstrated associations with several types of cancer. Here we examined the expression and potential function of the ZFAS1 in nasopharyngeal carcinoma (NPC).
METHODS: We detected ZFAS1 expression in GSE12452, a human microarray dataset, and NPC cell lines. Small interfering RNA against ZFAS1 was used to elucidate the cellular functions of ZFAS1 using MTT, colony formation, cell cycle, cell apoptosis, transwell invasion and migration and western blot assays. An activator of the PI3K/AKT signaling pathway (740Y-P) was used to determine the contribution of PI3K/AKT.
RESULTS: ZFAS1 was significantly upregulated in NPC tissues and cell lines. Silencing ZFAS1 significantly inhibited cell proliferation and invasion, arrested cell cycle progression and promoted cell apoptosis, as well as reduced epithelial-mesenchymal transition. Moreover, 740Y-P could rescue the effects of ZFAS1 knockdown on proliferation, apoptosis and invasion in 5-8F cells.
CONCLUSIONS: ZFAS1 might play an oncogenic role in NPC and facilitate cell proliferation and invasion via the PI3K/AKT signaling pathway in NPC cells.

Entities:  

Keywords:  EMT; ZFAS1; apoptosis; nasopharyngeal carcinoma; p-AKT

Mesh:

Substances:

Year:  2019        PMID: 31403940     DOI: 10.3233/CBM-182080

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  9 in total

Review 1.  Long non-coding RNAs in nasopharyngeal carcinoma: biological functions and clinical applications.

Authors:  Yao Tang; Xiusheng He
Journal:  Mol Cell Biochem       Date:  2021-05-17       Impact factor: 3.396

2.  IncRNA ZFAS1 contributes to the radioresistance of nasopharyngeal carcinoma cells by sponging hsa-miR-7-5p to upregulate ENO2.

Authors:  Jiaojiao Peng; Feng Liu; Hong Zheng; Qi Wu; Shixi Liu
Journal:  Cell Cycle       Date:  2020-12-20       Impact factor: 4.534

3.  The role of blood lnc-ZFAS1 in acute ischemic stroke: correlation with neurological impairment, inflammation, and survival profiles.

Authors:  Gang Wang; Ying Zhou; Tingting Zhong; Aixia Song; Qian Xue
Journal:  J Clin Lab Anal       Date:  2021-12-30       Impact factor: 2.352

Review 4.  Emerging roles of lncRNA in Nasopharyngeal Carcinoma and therapeutic opportunities.

Authors:  Haihua Wang; Weiyuan Wang; Songqing Fan
Journal:  Int J Biol Sci       Date:  2022-03-28       Impact factor: 10.750

5.  lncRNA ZFAS1 promotes the ox-LDL induced proliferation, invasion and migration of vascular smooth muscle cells.

Authors:  Hao Wang; Huajie Hu; Junjie Ma; Yafeng Jiang; Ruifei Cheng
Journal:  Exp Ther Med       Date:  2021-06-04       Impact factor: 2.447

6.  Upregulation of lncRNA ZFAS1 promotes lung adenocarcinoma progression by sponging miR-1271-5p and upregulating FRS2.

Authors:  Gang Fan; Jin Jiao; Feng Shen; Fulu Chu
Journal:  Thorac Cancer       Date:  2020-06-08       Impact factor: 3.500

7.  LINC00942 Promotes Tumor Proliferation and Metastasis in Lung Adenocarcinoma via FZD1 Upregulation.

Authors:  Ronghua Wang; Xiuyun Wang; Jingtao Zhang; Yanpei Liu
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

Review 8.  Role of PI3K/AKT pathway in cancer: the framework of malignant behavior.

Authors:  Ningni Jiang; Qijie Dai; Xiaorui Su; Jianjiang Fu; Xuancheng Feng; Juan Peng
Journal:  Mol Biol Rep       Date:  2020-04-24       Impact factor: 2.742

9.  Long noncoding RNA FAM225B facilitates proliferation and metastasis of nasopharyngeal carcinoma cells by regulating miR-613/CCND2 axis.

Authors:  Weijun Dai; Yi Shi; Weiqi Hu; Chenjie Xu
Journal:  Bosn J Basic Med Sci       Date:  2022-02-01       Impact factor: 3.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.